Sunday, 18 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange

Latest announcements

Every corporate announcement our alert engine sent, newest first: orders, results, earnings calls, fund raises, board meetings and more.

17:13 IST NSE
Production StartedHi-Green Carbon Ltd HIGREEN

Hi-Green Carbon Production Started

Hi-Green Carbon Limited commenced commercial operations at its new 100 TPD tyre pyrolysis plant in Madhya Pradesh. This expansion increases aggregate group capacity to 300 TPD.

Value
₹49.67 Cr
17:11 IST NSE
Business UpdateAkiko Global Services Ltd AKIKO

Akiko Global Services Business Update

Akiko Global Services reported April 2026 turnover of ₹21.02 Crore, achieving 249% year-on-year growth. This estimate demonstrates significant operational expansion compared to previous performance.

Value
₹21.02 Cr
Execution
April 2026
17:10 IST NSE
Management ChangeTAKE Ltd TAKE

TAKE Management Change

Take Solutions Limited appointed Sunil Patra as Managing Director and CFO for a five-year term. This leadership change aims to strengthen operational and financial management.

Execution
60 months
17:09 IST BSE
Board Meeting DateBLB Ltd BLBLIMITED

BLB Board Meeting Date

BLB Limited scheduled a board meeting on May 27, 2026, to approve audited financial results. The trading window remains closed for designated persons until result publication.

17:07 IST NSE
Management ChangePuravankara Ltd PURVA

Puravankara Management Change

Puravankara Limited appointed Mr. Subrahmanya Gupta Boda as Chief Technology Officer effective May 19, 2026. The move strengthens senior leadership to drive digital transformation initiatives.

17:07 IST NSE
Insolvency PetitionDpsc Limited DPSCLTD

Dpsc Insolvency Petition

India Power Corporation entered the Corporate Insolvency Resolution Process following an NCLT order. A management meeting chaired by the Resolution Professional is scheduled for May 27.

17:07 IST BSE
Earnings CallSenores Pharmaceuticals Ltd SENORES

Senores Pharmaceuticals Earnings Call: Key Takeaways

Senores Pharmaceuticals delivered a blockbuster FY26, significantly outperforming guidance with 62% revenue growth and 108% PAT growth, driven by US regulated market expansion.